Literature DB >> 20643637

Chronic leukocytosis associated with clozapine treatment.

Michael A Sopko1, Charles F Caley.   

Abstract

Clozapine is an important second-generation antipsychotic that is reserved for patients with refractory schizophrenia. Unfortunately, clozapine is also associated with a number of adverse effects, with agranulocytosis being one of the chief concerns. Interestingly, patients who receive clozapine treatment may occasionally experience elevations in their total white blood cell count (WBC). In some of these patients, the leukocytosis may be persistent. We report the case of a patient with refractory schizophrenia who is treated with clozapine and who experienced chronic leukocytosis. A brief review of the literature addressing clozapine-associated leukocytosis follows the case report.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20643637     DOI: 10.3371/CSRP.4.2.6

Source DB:  PubMed          Journal:  Clin Schizophr Relat Psychoses        ISSN: 1935-1232


  2 in total

1.  Leucocytosis in clozapine-treated patients as predictor of loss of treatment response?

Authors:  Vincenzo Prisco; Teresa Iannaccone; Umberto Volpe; Michele Fabrazzo
Journal:  BMJ Case Rep       Date:  2015-06-01

2.  Leukocytosis after Clozapine Treatment in a Patient with Chronic Schizophrenia.

Authors:  Aslıhan Polat; Uğur Çakir; Nermin Gündüz
Journal:  Noro Psikiyatr Ars       Date:  2016-03-01       Impact factor: 1.339

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.